San Diego-based Mpex Pharmaceuticals Inc. April 14 announced that it has entered into agreements with Axcan Pharma Inc. under which Axcan will acquire Mpex and its lead product candidate, Aeroquin.
Aeroquin is a proprietary aerosol formulation of levofloxacin, which is currently in phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis. All assets not associated with Aeroquin, including financial and human resources, will be spun out of Mpex and into a newly formed company. The new company will remain in San Diego, Mpex said.
Axcan, a Canadian company, will make an upfront payment to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.